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Population Genomics in 2016 
In 2000, the Human Genome project was announced as completed. The $3 billion dollar endeavor was 
heralded as ushering in a new era of medical science. This grand announcement was met with 
excitement, but also skepticism from those in the field of genetics. The manuscript detailing results of 
the Human Genome Project was published in 2003 (Human Genome Project website). And while many 
advances have come about since the publication of this data, the “new era of medicine” has not yet 
been realized. This cutting edge technology has allowed us to sequence the genome, but has outpaced 
our ability to interpret the information embedded within that sequence. This could be equated to  
learning to read; we have so far learned the alphabet, but are still learning how to sound out the words.  
If Genetics is the study of the spelling, origins and functions of individual genes, Genomics could be said 
to take a broader view, one that encompasses all of an organism’s genes and how they relate to each 
other, and the environment. One expectation of the Human Genome Project data was that it would 
revolutionize so called “personalized medicine,”  a buzzword in genetics/genomics as well as other 
medical fields. In 2014 President Barack Obama coined the term “precision medicine.” ( (PrecisionMed)) 
“Precision medicine” has no specific definition but encompasses the idea of “the right test/treatment for 
the right patient/family at the right time.” The office of Public Health Genomics at the CDC headed by 
Muin Khoury, MD, PhD has spearheaded much of the work in integrating genomic advances into public 
health initiatives.  
 The Geisinger Health System in central and eastern Pennsylvania has long been committed to excellent, 
affordable patient care. Most recently, they instituted the “ProvenCare system,” offering limited refunds 
for patients unsatisfied with their care. Geisinger was at the forefront of the use of electronic medical 
records, but went a step further, using the information in an integrative fashion to facilitate research 
while improving patient care. They created a novel system of research from the EMR that has since been 
3 | P a g e  
 
reproduced by many other centers. (Leader et al 2015). This has include studies looking at 
environmental risk through population incidence.  
In 1968, James Wilson and Gunner Jungner published Principles and Practice of Screening of Disease to 
delineate guidelines for health-related universal screening. (Wilson and Jungner 1968) The central 
tenants outlined within are the bedrock of our current understanding and practice of universal screens. 
For population screening especially, all new tests must “pass” these rules set down nearly 50 years ago.  
These include ideas such as feasibility, cost effectiveness and available intervention. Ingrained in the 
analysis, Wilson and Jungner note the importance of a “continuing process.” Incredibly the principles 
still apply to a diverse number of conditions today, from population mammograms to newborn 
screening. The importance of their treatises is reflected in the fact that current debates on the topic of 
population screening still recognize the importance of Wilson and Jungner in their discourse. 
The field of genomics is relatively uncharted territory, and the ever-shifting and expanding landscape is 
fraught with ethical and societal challenges which will require evolving strategies to navigate 
successfully. In this paper, I will explore some of these challenges and how the Geisinger 
MyCode/GenomeFirst program has developed unique approaches to addressing them, thus shaping the 
future of precision medicine. 
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Background 
Over the years, genetic testing has become more prevalent, more sensitive, and more broadly based. 
Karyotype, the ability to look at chromosomes under a microscope to identify structural changes, has 
been available since the 1960s. This test can identify extra or missing chromosomes, such as the extra 
copy of chromosome 21 in Down syndrome . A common analogy is that the human genome is a recipe 
for a human. If one were to imagine the chromosomes as recipe books lined up on a shelf, a karyotype 
would be like auditing the shelf to see if all the books are there. 
 In the 1990s, microarrays were developed that were more sensitive than karyotypes and could detect 
smaller changes in the chromosomes. Continuing the previously analogy, microarray is like opening each 
recipe book and counting the pages. Missing or extra pages can interfere with the recipe, as missing or 
extra genetic information can impact (usually deleteriously) human health and development.  
One benefit of microarray is that it can screen for many conditions all at once. The increased sensitivity 
of this test is a double-edged sword, however.  In some cases, microarrays are easily interpreted if the 
deletion or duplication is already well-known and associated with a described syndrome. Commonly, 
however, microarrays also reveal more variants of unclear significance. While some of these small 
chromosome variants represent normal human variation, some cause disease, and it is not always easy 
to differentiate the two. One of the common techniques used to tease this out is testing the parents. If 
one of the parents has the same genetic change seen in the child, but does not have similar clinical 
issues, the change is expected to have little or no effect.  
As more and more research is done, there is greater appreciation of the spectrum of disorders that can 
be seen as a result of a single genetic change. Take, for instance the duplication of chromosome 15 at 
15q11.2 (Mefford 2012).  A common variant found on microarray, it occurs in about 1% of children with 
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autism . Initially when this variant was identified, parents were tested (although presumably not autistic) 
and found to also have the duplication, causing geneticists to dismiss the 15q11.2 duplication as a 
normal population variant. Over time, however, it was found that many of the parents or other family 
members had subtle symptoms of autism or psychiatric disorders such as bipolar or schizophrenia. The 
presence of the 15q11.2 duplication does not absolutely mean that disease will develop, but is a risk 
factor. This is the world of variant interpretation with variable penetrance and expressivity (and 
something that will keep geneticists employed for a long time). (Richards 2015) 
The next phase of genetic testing was and is exome testing. Exomes are the expressed parts of the 
genome but constitute only about 2-3% of all of our DNA the exome is analogous to the nouns and verbs 
- the major players that convey the majority of meaning.  The whole genome would be all of the words 
and spaces and sentences in a book as well as the paper itself, cover, etc. There are other important 
elements in between, but these are still poorly understood by scientists. Whole exome testing allows 
the clinician to test for virtually every genetic condition at once (with the exception of a few specific 
categories of genetic disease that are caused by mechanisms other than simple gene misspellings.)But 
all of us have likely hundreds of variations in our genes. The majority of these have little or no impact, 
and we are searching for the one that has a large impact –the proverbial needle in a haystack. Despite 
its technical challenges, whole exome testing has become the test of choice in many circumstances 
because it is so broad-based.  
In addition to its growing use in the clinical setting, exome testing has become one of the more popular 
means of research testing. Instead of examining one gene at a time, exome testing allows for the 
analysis of thousands of genes at the same time. If we estimate that the exome contains about 22,000 
genes (and we still do not know the exact number), only about 12,000 have known diseases associated. 
Therefore there are many genes that are still to be discovered. Additionally interaction between genes 
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can be better studied by looking broadly at a person’s genome. And the next iteration of this will be 
whole genome sequencing, essentially looking at all the information available. 
The public health issue with exome/genome testing is that returning results in one person has 
implications for many other members of that person’s family. Similar to the 15q11.2 duplication, a 
variant might or might not cause disease. It may simply cause increased susceptibility to disease, or late-
onset disease. But another family member with the same gene variant could be affected differently.. 
One long time ethical principle of genetic testing is that minors should not be tested for adult-onset 
conditions. (Vears 2015) The theory is that the child should be able to give informed consent to be 
tested for conditions that arise in adulthood.  
The all-inclusive nature of exome testing brings with it unintended consequence of identifying genetic 
changes which cause adult-onset diseases such as cardiomyopathies and cancer susceptibility 
syndromes. When these mutations are identified, theoretically those results could be masked from 
children, but importantly these risks could be shared with relatives such as parents. A male child with a 
BRCA1 mutation causing hereditary breast ovarian cancer is seemingly at low risk for developing these 
cancers (though other cancers could still arise later in life) but what if it was inherited from a parent, 
specifically his mother? BRCA1 mutations constitute an approximate 80% risk for developing breast 
cancer and 50% chance of developing ovarian cancer in a woman’s lifetime. There are measures that can 
be taken to reduce these risks, ranging from well proven screening regimens (for early detection) to 
prophylactic surgery, which significantly reduces the risk of developing cancer (but unfortunately not 
100%).  
In 2013, the American College of Medical Genetics and Genomics came out with guidelines stating that, 
for certain conditions, results should always be made available to the patients regardless of age. (Green 
2013) These ‘secondary findings’ as they were termed, were mostly adult-onset conditions in which 
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early intervention would ultimately benefit the patient. In general the conditions are associated with 
cancer or heart disease that manifests in the thirties or later. Many raised concern over this practice, 
calling it paternalistic to dictate what information patients receive. Proponents argued that genetic test 
results were not like other test results, and exceptions should be made in the standard results-reporting 
guidelines. Because of the controversy, in 2014 the guidelines were revised to allow patients to ‘opt-out’ 
of receiving these types of results. (ACMG guidelines revision 2014) 
While this new guideline was applied to clinical exome testing, it does not extend to research testing. 
There is ongoing debate regarding “the Common Rule,” a staple of current research thinking. Part of the 
Common Rule states that research participants do not necessarily get back individual test results. 
Broadly, this rule was adopted because the standards for research and clinical testing are different. But 
more realistically, returning results to research volunteers is a daunting task. Patients would need to be 
re-contacted, a clinical visit arranged, etc. But often studies have hundreds if not thousands of patients. 
In some cases, the results are esoteric and not clinically actionable. In other cases, it might be that the 
results are not applicable expect under specific circumstances. With exome testing a means for research 
testing reporting these potentially actionable results is one of the ongoing concerns for geneticists and 
researchers. 
 
Geisinger Health system and MyCode/GenomeFirst 
Geisinger Health system is based in central and eastern Pennsylvania and recently expanded to New 
Jersey as well. There are about 3 million people in the system. Since its founding over 100 years ago, 
Geisinger developed a reputation for patient-centric care. Additionally, it has emphasized high-quality 
andaffordable care with several novel and innovative systems in place. Nationally, it is renowned for this 
practice and the institution was able to attract their new CEO from UCLA. Dr. David Feinberg is well 
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known for patient-centered care as well as being a “servant leader” often giving patients and employees 
his personal e-mail or cellphone number to follow up( (10 things to know about Geisinger's new CEO: Dr. 
David Feinberg, 2016)).  He has pushed the project to be patient-care focused in a manner that is quite 
different from how most healthcare systems would deal with research. Geisinger was one of the first 
health systems to adopt EPIC as an electronic medical record and has expanded the role that EPIC plays 
in not only patient care but research. By encouraging good use of the system, Geisinger has been able to 
leverage data-mining in many novel methods.  ( (markerpaper)) 
MyCode is the population-level health study being done at Geisinger Health System. Patients are 
consented to study to have an exome test combined with their rich genetic information as a powerful 
research tool. The uptake of the study has been breath-taking with over one thousand patients 
consented weekly. Translating the data from the estimated 250,000 research participants to clinical 
information is something that has not been attempted before. With the Geisinger MyCode system, it 
was decided to use the ACMG’s recommended list but add on for some additional genes that could have 
preventative processes in place and to meaningfully let participants know the results for their genetic 
testing. This process of “genomicly” identifying patients and then changing management is the 
“GenomeFirst” approach. Importantly this might have more implications for other family members than 
for the initial person identified. 
The other key factor that grew the eventual My Code project was teaming with a pharmaceutical 
company called Regeneron Pharmaceuticals. Regeneron had some success with new methods of drug 
development; rather than traditional small molecules, they created medications based on antibody 
properties. This method has proven to be faster to develop, have somewhat reduced side effects and, in 
the limited clinical studies, proven to be effective. Regeneron was looking to develop novel drug targets 
by looking at genetic risk and well-curated clinical characteristics, something that the Geisinger Health 
System was uniquely able to provide. Regeneron has had immense recent success following the  
9 | P a g e  
 
discovery of a gene associated with familial hypercholesterolemia called PCSK9. (Stein 2012). They 
created the first novel therapy for elevated cholesterol in over 30 years- a class of drug that is estimated 
to be worth over $1 billion dollars.  
Another important feature of GenomeFirst is what is termed “just in time” information. The traditional 
medical model stipulates that the patient only have the test done that they are interested in. For 
example, if you want to know how a patient would potentially react to a medication you may consider 
how they reacted to a smaller dose or similar medication. If you were to use pharmacogenomic testing 
(genetic testing related to medication action or metabolism) to guide treatment it could be ordered, but 
this inherently creates a delay in use. With “just in time” testing for pharmacogenomics for example, the 
relevant genetic information would be present in the background of the EMR but when you triggered 
the system by ordering a medication on the list, it would immediately pull the information for reference. 
Pre-emptive testing is only possible and time and cost effective when the test can be picked up within 
the context of other testing or as part of a broader panel.  
The Geisinger patient population also uniquely allows for the use of well-defined family data to aid in 
interpretation of novel genetic variants identified by MyCode. Linkage analysis is a tool that has been 
used for decades by geneticists to find genes of interest. (Staples 2015) Using a new computational tool 
called Primus it is possible to link multiple MyCode participants together and determine their degree of 
relationship. It is therefore possible to create linkage pedigrees just based on available information, 
without relying on patient-reported information. The advantage is that by looking at the intersection of 
objective data points, say the presence of a change in a breast cancer susceptibility gene in several 
women and the incidence of breast cancer in that population, it might be possible to elucidate if that 
genetic change is a contributing factor. But importantly, the negative is also informative- say someone 
has a sister with early onset breast cancer and her sister has a variant that is of unknown significance. If 
one sister does not have a history of breast of cancer without the variant and another sister does have 
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breast cancer with the variant, it is possible to infer that the variant may link to be causative. This does 
not prove to the variant’s pathogenicity but it provides more evidence. Going out further in the family 
may even provide more information and this has been proven with the MyCode project. 
A national program called the Precision Medicine Initiative (PMI) has taken center-stage with political 
capital and, importantly, funding available to implement it. The project, launched in early 2015, aims to 
leverage the advancements made in genomics, bioinformatics and health information to aid in discovery 
and “precision” healthcare. It was a significant strategic goal for the Obama Administration. Furthering 
efforts started in the Electronic Medical Records and Genomics (EMERGE) network and Clinical 
Sequencing Exploratory Research (CESR) grants, the PMI hopes to establish a repository of one million 
(or more) samples with extensive associated biological data. Geisinger is poised to play a very crucial 
role in this process, given the already impressive recruitment to date, and the fact that many of the 
planned initiatives for the PMI have already been implemented at Geisinger. 
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Population Genetics and Wilson and Jungner 
Wilson and Jungner Classic Screening Criteria 
1. The condition sought should be an important health problem. 
2. There should be an accepted treatment for patients with recognized diseases. 
3. Facilities for diagnosis and treatment should be available. 
4. There should be a recognizable latent or early symptomatic stage. 
5. There should be a suitable test or examination. 
6. There should be acceptable to the population. 
7. The nature history of condition, including development from latent to declared disease, should 
be adequately understood. 
8. There should be an agreed policy on whom to treat as patients. 
9. There cost of case-finding (including diagnosis and treatment of patients diagnosed) should be 
economically balanced in relation to possible expenditure on medical care as a whole. 
10. Case-finding should be a continuing process and not a “once and for all” project. 
 
In multiple publications since 2009, the CDC Office of Public Health genomics has classified conditions in 
which genomic and family history have a base of synthesized evidence supporting implementation into 
practice. Using various sources including national panels, the US Preventative Taskforce (USPTF) and 
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) recommendations, among the 
three most well described are Familial hypercholesterolemia (FH), hereditary breast and ovarian cancer 
(HBOC) and Lynch syndromes (hereditary susceptibility to colorectal and other cancers.) These disorders 
are specifically noted as they are autosomal dominant (meaning all first degree relatives are at 50% risk) 
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and importantly have well established guidelines for management.  Collectively, using approximations 
based on incidence, these three disorders will be found in around 1-2% of the general population. It is 
also widely cited that the current incidence rates are likely too conservative and may be 
underestimating the true population incidence. These disorders additional cross ethnic, social and 
economic boundaries.  
Fundamentally, our current understanding of these conditions comes from the inherent bias of a 
personal or family history of disease. These bias all subsequent observations, screens and interventions. 
There is a bias toward pathogenicity since genetic testing currently requires a sufficient personal or 
family history of cancer to justify test usage. For example, Lynch syndrome screening often starts with 
tumor testing and subsequent family history information gathering. The variability in penetrance and 
expression are more difficult to gauge in the general population.  
One strategy to combat these disorders is universal population screening. Universal screening does have 
the advantage of inclusion but may miss those patients that would develop disease prior to normal age 
screening (for example breast screening starting at age 40, colonoscopy starting at age 50 and lipid 
screening around age 8). Universal screening also accepts a bias toward false positives in order to 
reduce false negatives with considerable health care expenditures and personal anxiety as a result. This 
specific tension is well noted in the USPTFs repeated attempts to change breast cancer screening and 
the public’s anxiety with doing so.  Universal screening has also shown to be an area with significant 
health disparity (Belasco 2014).  
While population-level genomics is in its infancy, the thought processes are becoming more clearly 
aligned with the principles set forth by Wilson and Jungner. The cost of genomic testing has decreased 
and the infrastructure to handle the complex results has increased, a testament to forward thinking in 
the genetics/genomics community (though there is still a considerable way to go). From the ACMG’s list 
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of secondary findings to leadership from the CDC Office of Public Health Genomics, a framework for 
screening processes has been developing.  The possible general application of exomes is not as far-
fetched as once thought, and programs such as the GenomeFirst at Geisinger Health System and the 
upcoming Precision Medicine Initiative will provide important information about the viability of such 
systems. 
One important difference between current universal screening (essentially secondary prevention) and 
genomic screening is the allowance for primary prevention of the disease state. For FH and HBOC, there 
are well established management guidelines to alleviate the disease burden in the affected group. For 
FH, aggressive use of cholesterol lowering therapies and screening for atherosclerosis can be primary 
prevention of myocardial infarction or strokes. Those with FH typically have their first cardiovascular 
event in their 30s or 40s. Additionally, mitigating other risk factors such as diet, diabetes or 
hypertension may be more aggressively pursued for those with FH. In the case of HBOC, national 
guidelines note the value of prophylactic mastectomy and oophorectomy in the high risk population. 
While neither will fully eliminate the risk, it does significantly reduce the risk.  There is also use of 
prophylactic medications such as tamoxifen and reducing estrogen exposure with oophorectomy 
reducing the risk for breast cancer. One could also make the argument that colonoscopy with polyp 
removal could be considered primary prevention in Lynch syndrome. Early detection of cancer results in 
improved health outcomes in HBOC and Lynch syndrome. MRI of the breast is well established in those 
with HBOC but is too costly as a general population screen. Another advantage of genomic screening 
might be that it would allow aggressive screening to be targeted to a very specific increased-risk 
population (MRI of the breast is well established to result in improved health outcomes in HBOC and 
Lynch syndrome, but is too costly as a general population screen) while utilizing universal screening to 
focus better on an older population with sporadic disease and reduce false positives (mammograms are 
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especially difficult in younger women and result in more unnecessary biopsies) thus better utilizing 
healthcare dollars.. 
There are still many hurdles to the use of genomics for population screening. While cost have 
significantly reduced, the feasibility of coverage is difficult to justify at this time. More studies need to 
be done looking at the economic ramifications. It has taken many years to show the economic value 
with tumor screening for Lynch syndrome but the evidence is quite substantial now; and interestingly 
the cost-analysis included cascade testing in other family members, which would also be available with 
genomic screening. {Gudgeon 2011] 
While the infrastructure to manage these conditions is there currently, increasing the population that 
needs to be screened will likely be a burden to the current system. There is a significant shortage of 
trained genetic professionals, and other types of medical professionals may not be prepared to handle 
the added burden of management for FH, Lynch and HBOC without further guidance. This is not an 
unprecedented undertaking and the right means and education could be done with professional 
societies to bridge this gap. Along the same lines, insurance coverage for screening would have to be 
updated but economic/societal benefit would aid in demonstrating its long-term value to insurance 
companies and the public.   
There is a fundamental question that needs to be addressed as well: does identification of a pathogenic 
variant give the diagnosis alone? Discovery of deleterious mutation should not constitute diagnosis of 
that condition. On one level, from the patient perspective, discovery of a BRCA mutation does not mean 
that the patient has cancer; only that they are at significantly increased risk of developing cancer. This is 
not a minor point in return of results. Most current clinical criteria are designed to look at the likelihood 
of having a mutation, often in those already identified with disease. For example, the various criteria for 
FH all include a current diagnosis of hypercholesterolemia plus other factors. Some even include the 
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identification of a genetic variant. The Lynch criteria often emphasize the family history and tumor 
testing in an effected patient. There are various breast cancer programs available that look at the 
multitude of breast cancer risks. But what of patients who have not yet had manifestation of disease? 
Simplistically this occurs in cascade testing from affected patients to their relatives. And it is this very 
population that underscores the value of genomic testing: identification and prevention prior to disease 
development. But these are also families that have a history of cancer and therefore maybe other 
shared traits (genetic, environmental, and behavioral) that contribute to this “familial” risk.  
Racial and socioeconomic differences in the early adoption of genomics may exacerbate existing health 
disparity. Because most participants in genomic research to date have been Caucasian, those of non-
Caucasian backgrounds are still likely to be underdiagnosed because of a lack of identification of unique 
pathogenic variants in that population. For example, in BRCA, while there have been laudable 
improvements in reducing the number of variants of uncertain significance, those of minority 
backgrounds are still twice as likely to have a variant of uncertain significance as those of Caucasian 
background. This is also an opportunity for universal screening to improve the landscape of genomic 
healthcare; better characterization of variants will occur with more information. A similar phenomenon 
has occurred with newborn screening for Fabry disease in Japan (Inoue 2013). This is a disorder that can 
have quite variable manifestations and the screening done in Japan has been important in helping better 
understand the disorder. 
One of Wilson and Jungner’ s criteria is especially salient in the discussion of genomic screening: “case 
findings should be a continuing process and not a ‘once and for all’ project.” The process of genomic 
screening will be re-iterative and a learned process that will better be able to clarify some of the 
questions raised. Like newborn screening there will need to be integrated education, testing, clinical 
services and program management. The evidence will also need to be provided for clinical utility in 
addition to clinical validity. The program should be an opt-in as to ensure informed choice, confidentiality 
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and respect for autonomy. And along those same lines, there should not be discrimination against those 
who choose to opt-out especially a concern as health plans create incentives for accepted screening.  
Ethical issues 
The ethical issues of such a complex study are quite myriad. Starting at the beginning with a 
fundamental question impacting much of clinical research today: how often are patients being properly 
consented? Informed consent for complex genetic information is quite difficult with nuanced language 
and complex concepts such as DNA and understanding of risk (e.g. 1.3 relative risk, 30% increased risk, 
30% absolute risk). Additionally, the MyCode study is primarily being funded through a pharmaceutical 
company whose fervent hope is that they will discover some drugs to develop from this novel approach. 
In the wake of the outcry regarding Henrietta Lack and HeLa cells, the balance must be properly 
structured for patient autonomy/research.  
The nature of MyCode study was that patients were consented at least 8 years ago. We wondered how 
many remembered that they were enrolled in a study. Anecdotally, we have seen that patients do not 
remember, because they have tried to sign up again for the same study. Additionally, from a researchers 
perspective, the consent has changed and many patients will have to have be re-consented in order to 
update their knowledge and expectations. The entire release of results in such a broad manner is not 
specifically been done in other large study populations, and the return of results portion of the MyCode 
project will be quite informative to the genomics community at large.  
There are some clear weaknesses in the Geisinger MyCode study. The most oft sited is the lack of racial 
diversity. The strength of a stable population also reflects a fairly homogenous Caucasian population. 
This is a significant and on-going struggle in large genetic studies. Going back to genome wide 
association studies, similar criticisms were made that those groups do not reflect the general US 
population (let alone the world population). Geisinger is increasing its reach with the annexation of new 
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health care systems, but this will only slightly change the challenging demographics. Similarly, the socio-
economic diversity is also not typical, however unlike many other genomic populations, the Geisinger 
population is skewed to slightly less educated and less wealthy than the average US population. The 
population also skews significantly older, again reflecting the area. This however may be a strength for 
genetic findings (though perhaps a weakness for genetic intervention). If a concern is penetrance of a 
disorder, an older population better reflects those truly affected by a genetic change. A younger 
population would not give information about whether a person would develop disease in the future 
(though with the long term longitudinal nature of this study it should be picked up eventually).  
Another limitation is the data available from the EMR. While the data quality is quite long as a strength, 
it is difficult to assess the quality of the data as there is no objective criteria available. Certainly the 
person who has only a limited number of encounters with the healthcare system will provide less 
information than the person followed for many decades. But there are likely limitations as to what is 
entered into in the EMR as well. Documentation certainly can contain errors but also accidental and 
presumptive information as well. Geisinger has also been at the forefront of a movement to have 
records fully open to patients and is implementing something called the “shared note” where patients 
and providers together create the documentation for an encounter.  
Geisinger is specifically a community hospital, albeit on a scale that makes it an exception as a non-
university system. Comparable hospitals such as Cleveland Clinic and Mayo Clinic have very different 
focuses of care, often at the cutting of practice rather than at the cutting edge of care. However a key 
part of what is being done at Geisinger is specifically designed to be replicable. The genomics program 
as well has been set up to be scalable even with a smaller genomics presence and in anticipation of 
reducing technology costs.   By starting in a research setting, Geisinger can show the value for care, 
increasing acceptance importantly by insurance companies and the government services.  
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Application of the Wilson and Jungner Criteria should continue to be strongly associated with the 
exciting developments in population genomics.  We should heed the warning laid out by this omniscient 
pair of Wilson and Jungner 48 years ago:  
“The central idea of early disease detection and treatment is essentially simple. However, the path to its 
successful achievement(on the one hand, to bringing treatment those with previously undetected 
disease, and on the other, avoiding harm to those persons not in need of treatment) is far from simple 
though sometimes it may appear deceptively easy.” 
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